Open Your Mind
Is the pharmaceutical industry overly reluctant to accept new ideas?
Roisin McGuigan |
It is universally acknowledged that the pharmaceutical industry can be conservative and slow to embrace change. With the health and safety of patients at stake if something should go wrong, this is hardly surprising. But does pharma’s skepticism run too deep?
I recently had the pleasure of speaking with Alex Zhavoronkov, CEO of Insilico Medicine – a passionate supporter of artificial intelligence (read more here) and a true believer of its transformative potential in drug discovery. Insilico Medicine is working with Juvenescence to identify preclinical compounds, but there are other companies grabbing headlines in the AI/pharma space; take BenevolentAI, which is attempting to gain new insight into the molecular mechanisms of disease and to match patients to the right drug. The company was valued at $2 billion after its latest round of funding (1).
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine